Aims
 
The UKHDN aims to bring together scientists and clinicians with an interest in Huntington’s disease, in order to expedite research into treatments.
 
One of the major driving forces behind the establishment of the network was the recognition that historically, large clinical trials with this patient population have been difficult because of small population samples.
 
The Network has two main aims:
-To establish a large cohort of well-characterised patients with a view to rapid implementation of clinical trials as and when new therapies emerge;
-To facilitate clinical studies aimed at increasing understanding of the pathogenic processes underlying the neural damage seen in HD.
 
 
Background
 
Established in January 2003, the United Kingdom Huntington’s disease Network (UKHDN) aims to bring clinicians and basic scientists together in order to work towards effective management and treatment of people either at-risk of or affected by, Huntington’s disease (HD).
 
The Network is coordinated from Cardiff University, where management and communication of network activities is conducted for over 20 UK member sites.  The Chair of the UKHDN is Professor Anne E. Rosser and the Steering Committee is listed above. The UKHDN is affiliated with and has close working relationship with the EHDN; all UKHDN sites joined the EHDN in 2004.


Financial Support
The UKHDN was founded with financial support from the Dunhill Medical Trust, with assistance from the Huntington's Disease Association.
We thank CHDI Inc. and for additional financial support via links with the EHDN.